Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
AtriCure to hold an investor event » 13:45
09/28/22
09/28
13:45
09/28/22
13:45
ATRC

AtriCure

$39.57 /

+1.32 (+3.45%)

Investor Education Event…

Investor Education Event entitled, "Hybrid AF Therapy to be held on September 28 at 2 pm. Webcast Link

ShowHide Related Items >><<
ATRC AtriCure
$39.57 /

+1.32 (+3.45%)

ATRC AtriCure
$39.57 /

+1.32 (+3.45%)

08/03/22 Needham
AtriCure price target raised to $65 from $55 at Needham
08/03/22 Piper Sandler
AtriCure price target lowered to $55 from $90 at Piper Sandler
07/18/22 Stifel
AtriCure price target lowered to $50 from $70 at Stifel
07/05/22 Piper Sandler
Bottom in med tech shares is 'getting close,' says Piper Sandler
ATRC AtriCure
$39.57 /

+1.32 (+3.45%)

Hot Stocks
Blue Apron rises 16.0% » 12:00
09/28/22
09/28
12:00
09/28/22
12:00
APRN

Blue Apron

$5.83 /

+0.82 (+16.37%)

Blue Apron is up 16.0%,…

Blue Apron is up 16.0%, or 80c to $5.81.

ShowHide Related Items >><<
APRN Blue Apron
$5.83 /

+0.82 (+16.37%)

APRN Blue Apron
$5.83 /

+0.82 (+16.37%)

08/10/22 Lake Street
Blue Apron initiated with a Buy at Lake Street
07/20/22 Benchmark
Benchmark starts Blue Apron at Buy with turnaround not getting credit
07/20/22 Benchmark
Blue Apron initiated with a Buy at Benchmark
05/10/22 Canaccord
Blue Apron price target lowered to $10 from $12 at Canaccord
APRN Blue Apron
$5.83 /

+0.82 (+16.37%)

APRN Blue Apron
$5.83 /

+0.82 (+16.37%)

APRN Blue Apron
$5.83 /

+0.82 (+16.37%)

APRN Blue Apron
$5.83 /

+0.82 (+16.37%)

Conference/Events
AtriCure to hold an investor event » 11:19
09/28/22
09/28
11:19
09/28/22
11:19
ATRC

AtriCure

$38.96 /

+0.71 (+1.86%)

Investor Education Event…

Investor Education Event entitled, "Hybrid AF Therapy to be held on September 28 at 2 pm. Webcast Link

ShowHide Related Items >><<
ATRC AtriCure
$38.96 /

+0.71 (+1.86%)

ATRC AtriCure
$38.96 /

+0.71 (+1.86%)

08/03/22 Needham
AtriCure price target raised to $65 from $55 at Needham
08/03/22 Piper Sandler
AtriCure price target lowered to $55 from $90 at Piper Sandler
07/18/22 Stifel
AtriCure price target lowered to $50 from $70 at Stifel
07/05/22 Piper Sandler
Bottom in med tech shares is 'getting close,' says Piper Sandler
ATRC AtriCure
$38.96 /

+0.71 (+1.86%)

Recommendations
iRhythm should be bought after 25% pullback, says JPMorgan » 07:22
09/28/22
09/28
07:22
09/28/22
07:22
IRTC

iRhythm

$118.82 /

-1.37 (-1.14%)

JPMorgan analyst Allen…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IRTC iRhythm
$118.82 /

-1.37 (-1.14%)

IRTC iRhythm
$118.82 /

-1.37 (-1.14%)

09/22/22 JPMorgan
iRhythm price target raised to $190 from $185 at JPMorgan
09/12/22 JPMorgan
iRhythm analyst day to reaffirm bull thesis, says JPMorgan
09/02/22 Canaccord
iRhythm price target raised to $198 from $185 at Canaccord
08/05/22 BTIG
iRhythm price target raised to $178 from $155 at BTIG
IRTC iRhythm
$118.82 /

-1.37 (-1.14%)

IRTC iRhythm
$118.82 /

-1.37 (-1.14%)

Yesterday
Conference/Events
Cullinan management to meet virtually with BTIG » 12:27
09/27/22
09/27
12:27
09/27/22
12:27
CGEM

Cullinan

$12.28 /

+0.18 (+1.49%)

Virtual Meeting to be…

Virtual Meeting to be held on October 6 hosted by BTIG.

ShowHide Related Items >><<
CGEM Cullinan
$12.28 /

+0.18 (+1.49%)

CGEM Cullinan
$12.28 /

+0.18 (+1.49%)

CGEM Cullinan
$12.28 /

+0.18 (+1.49%)

Hot Stocks
Blue Apron rises 15.0% » 12:00
09/27/22
09/27
12:00
09/27/22
12:00
APRN

Blue Apron

$5.14 /

+0.65 (+14.48%)

Blue Apron is up 15.0%,…

Blue Apron is up 15.0%, or 67c to $5.14.

ShowHide Related Items >><<
APRN Blue Apron
$5.14 /

+0.65 (+14.48%)

APRN Blue Apron
$5.14 /

+0.65 (+14.48%)

08/10/22 Lake Street
Blue Apron initiated with a Buy at Lake Street
07/20/22 Benchmark
Benchmark starts Blue Apron at Buy with turnaround not getting credit
07/20/22 Benchmark
Blue Apron initiated with a Buy at Benchmark
05/10/22 Canaccord
Blue Apron price target lowered to $10 from $12 at Canaccord
APRN Blue Apron
$5.14 /

+0.65 (+14.48%)

APRN Blue Apron
$5.14 /

+0.65 (+14.48%)

APRN Blue Apron
$5.14 /

+0.65 (+14.48%)

APRN Blue Apron
$5.14 /

+0.65 (+14.48%)

Options
Blue Apron call volume above normal and directionally bullish » 10:45
09/27/22
09/27
10:45
09/27/22
10:45
APRN

Blue Apron

$5.13 /

+0.64 (+14.25%)

Bullish option flow…

Bullish option flow detected in Blue Apron with 14,548 calls trading, 3x expected, and implied vol increasing almost 9 points to 187.10%. 9/30 weekly 5 calls and Oct-22 5 calls are the most active options, with total volume in those strikes near 4,800 contracts. The Put/Call Ratio is 0.10. Earnings are expected on November 8th.

ShowHide Related Items >><<
APRN Blue Apron
$5.13 /

+0.64 (+14.25%)

APRN Blue Apron
$5.13 /

+0.64 (+14.25%)

08/10/22 Lake Street
Blue Apron initiated with a Buy at Lake Street
07/20/22 Benchmark
Benchmark starts Blue Apron at Buy with turnaround not getting credit
07/20/22 Benchmark
Blue Apron initiated with a Buy at Benchmark
05/10/22 Canaccord
Blue Apron price target lowered to $10 from $12 at Canaccord
APRN Blue Apron
$5.13 /

+0.64 (+14.25%)

APRN Blue Apron
$5.13 /

+0.64 (+14.25%)

APRN Blue Apron
$5.13 /

+0.64 (+14.25%)

APRN Blue Apron
$5.13 /

+0.64 (+14.25%)

Hot Stocks
Blue Apron rises 6.6% » 09:47
09/27/22
09/27
09:47
09/27/22
09:47
APRN

Blue Apron

$4.75 /

+0.26 (+5.79%)

Blue Apron is up 6.6%, or…

Blue Apron is up 6.6%, or 29c to $4.76.

ShowHide Related Items >><<
APRN Blue Apron
$4.75 /

+0.26 (+5.79%)

APRN Blue Apron
$4.75 /

+0.26 (+5.79%)

08/10/22 Lake Street
Blue Apron initiated with a Buy at Lake Street
07/20/22 Benchmark
Benchmark starts Blue Apron at Buy with turnaround not getting credit
07/20/22 Benchmark
Blue Apron initiated with a Buy at Benchmark
05/10/22 Canaccord
Blue Apron price target lowered to $10 from $12 at Canaccord
APRN Blue Apron
$4.75 /

+0.26 (+5.79%)

APRN Blue Apron
$4.75 /

+0.26 (+5.79%)

APRN Blue Apron
$4.75 /

+0.26 (+5.79%)

APRN Blue Apron
$4.75 /

+0.26 (+5.79%)

Hot Stocks
Cybin to acquire license to tryptamine-based molecules from Mindset for $500,000 » 08:17
09/27/22
09/27
08:17
09/27/22
08:17
CYBN

Cybin

/

+

, MSSTF

Mindset Pharma

/

+

Cybin (CYBN) announced…

Cybin (CYBN) announced that, through its wholly-owned subsidiary Cybin IRL, it has entered into an agreement with Mindset Pharma (MSSTF) to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules from Mindset. Pursuant to the agreement, Cybin has paid Mindset a one-time license fee of $500,000 with additional milestones payable upon the successful completion of certain future milestones. Notably, the Agreement: provides Cybin access to a catalog of molecules that complement Cybin's current preclinical library, with both complementary chemistry and properties; expands Cybin's discovery and development platform to provide an enduring runway and pipeline of future drug candidates while broadening the space where Cybin has protected access to patent-eligible molecules and formulations and strengthens Cybin's intellectual property reach and scope of protection in support of continued investment in psychedelic therapeutics for mental health conditions. The agreement includes an initial license fee payment by Cybin to Mindset of $500,000 as well as additional clinical development milestone payments payable only upon the successful completion of certain milestones contemplated in the agreement. The milestone payments could total up to $9.5M, with the first milestone payment, in the amount of $500,000, payable upon completion of a Phase 1 clinical trial. At the sole discretion of Cybin, the milestone payments may be payable in cash or in common shares in the capital of Cybin, or a combination thereof, subject to the approval of the Neo Exchange and upon the successful completion of the Milestones, including the approval and commercialization of the first drug candidate. The agreement also contemplates a sales royalty of approximately 2% for all commercialized licensed products within the scope of the Agreement, which is customary for drug licensing agreements of this nature.

ShowHide Related Items >><<
MSSTF Mindset Pharma
/

+

CYBN Cybin
/

+

CYBN Cybin
/

+

08/24/22 Stifel
Cybin price target lowered to C$3 from C$8.25 at Stifel
06/23/22 Canaccord
Cybin undervalued relative to market size opportunity, says Canaccord
06/10/22 Canaccord
Cybin shares remain significantly undervalued, says Canaccord
04/13/22 H.C. Wainwright
H.C. Wainwright says Cybin preclinical data show continued innovation leadership
MSSTF Mindset Pharma
/

+

11/03/21 H.C. Wainwright
Mindset Pharma initiated with a Buy at H.C. Wainwright
CYBN Cybin
/

+

Hot Stocks
Mindset Pharma provides intellectual property license to Cybin » 07:32
09/27/22
09/27
07:32
09/27/22
07:32
MSSTF

Mindset Pharma

/

+

, CYBN

Cybin

/

+

Mindset Pharma (MSSTF)…

Mindset Pharma (MSSTF) announced an exclusive licensing agreement for Cybin (CYBN) to acquire intellectual property rights for a subset of Mindset's preclinical compounds. Under the terms of the Agreement, Cybin will license intellectual property related to preclinical compounds within Mindset's "Family 1" portfolio, excluding MSP-1014, Mindset's lead psychedelic drug candidate. "Over the last two years, Cybin has assembled a leading psychedelic drug development organization and we are pleased that our novel preclinical compounds have been recognized to potentially support their R&D pipeline. Both our companies share the same ultimate goal of discovering and developing superior new psychedelic treatments to better meet the needs of patients," said James Lanthier, CEO of Mindset Pharma. "This licensing agreement - Mindset's second such agreement to advance its innovations to clinical study - is another example of Mindset successfully executing on its scientific and business strategies. Coupled with our existing collaboration, Mindset now has multiple "shots on goal" for commercializing its innovations, with additional potential from its recently announced new families." The Agreement includes an initial payment by Cybin to Mindset of US $500,000 along with clinical development milestone payments which could total up to US $9,500,000 upon successful completion of agreed milestones, including the approval and commercialization of the first drug candidate. The agreement also contemplates a sales royalty of approximately 2% for all commercialized licensed products within the scope of the exclusive agreement, which is customary for drug licensing agreements of this nature.

ShowHide Related Items >><<
MSSTF Mindset Pharma
/

+

CYBN Cybin
/

+

MSSTF Mindset Pharma
/

+

11/03/21 H.C. Wainwright
Mindset Pharma initiated with a Buy at H.C. Wainwright
CYBN Cybin
/

+

08/24/22 Stifel
Cybin price target lowered to C$3 from C$8.25 at Stifel
06/23/22 Canaccord
Cybin undervalued relative to market size opportunity, says Canaccord
06/10/22 Canaccord
Cybin shares remain significantly undervalued, says Canaccord
04/13/22 H.C. Wainwright
H.C. Wainwright says Cybin preclinical data show continued innovation leadership
CYBN Cybin
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.